Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients with hormone receptor-positive, HER2-negative early breast cancer HRHER2- EBC who are at high risk of their cancer returning. This observational study includes both past and future phases to assess the clinical and pathological features, treatment choices, and outcomes of patients treated with CDK46 inhibitors ribociclib or abemaciclib combined with endocrine therapy in the adjuvant setting. The study also focuses on patients whose cancer returned during or within 12 months after finishing this adjuvant treatment. Participants are those who have started or are starting adjuvant treatment with ribociclib or abemaciclib along with endocrine therapy since January 1, 2021. This study does not involve assigning treatments but observes patients receiving these therapies in real-world settings. It gathers data on treatment patterns, recurrence, and clinical outcomes without altering patient care. During the study, researchers will collect and analyze data on patient health, tumor characteristics, and treatment responses. They will track invasive disease-free survival over 3 years as the main outcome, along with distant relapse-free survival, progression-free survival, and overall survival up to 5 years. Participants will provide consent for their data to be used, and their health status will be monitored through routine medical records and follow-ups. The study is expected to continue until August 2030.
Actively Recruiting
Researchers are conducting the PANThEON trial, a randomized, open-label, multicenter phase III study, to compare two chemotherapy approaches in patients with advanced pancreatic adenocarcinoma that cannot be surgically removed or has spread. The study aims to evaluate overall survival by comparing continuing modified FOLFIRINOX versus switching to gemcitabine plus nab-paclitaxel after initial induction chemotherapy. Eligible patients have stable or responding disease after about 3 months of initial mFOLFIRINOX treatment. During the study, all participants first receive induction chemotherapy with mFOLFIRINOX for up to 14 weeks, consisting of about six cycles every two weeks. Patients who show no disease progression are then randomly assigned to either continue mFOLFIRINOX Arm A or switch to gemcitabine plus nab-paclitaxel Arm B. Arm A treatments include oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil given every two weeks until progression or unacceptable side effects. Arm B treatments involve gemcitabine and nab-paclitaxel administered on days 1, 8, and 15 of each 28-day cycle until progression or toxicity. Participants will have tumor imaging before and after induction chemotherapy to assess response. Throughout the trial, researchers will monitor overall survival up to 48 months, along with other outcomes like progression-free survival, treatment failure time, response rates, quality of life, and treatment toxicity. Safety and disease status will be regularly assessed, and participants may continue treatment or withdraw as needed. The trial is expected to last until 2030, with ongoing follow-up for health status and outcomes.
Actively Recruiting
Researchers are studying patients experiencing arrhythmic storm, a serious heart condition characterized by frequent and sustained ventricular arrhythmias that do not respond to standard antiarrhythmic drugs. This international multicenter observational study aims to evaluate the safety and effectiveness of Percutaneous Stellate Ganglion Block PSGB in reducing arrhythmic relapses in such emergency cases. The study is coordinated by Fondazione IRCCS Policlinico San Matteo of Pavia, Italy, and addresses a gap in large-scale data on this procedure. Participants who meet the criteria will receive PSGB using either the anatomical or echo-guided approach. Depending on patient needs, the procedure may involve a single anesthetic injection or continuous anesthetic infusion via a catheter connected to a pump. The study compares the number of arrhythmic events and defibrillations before and after PSGB treatment and notes any complications occurring within 12 hours post-procedure. During participation, patients will be monitored closely for arrhythmic relapses using defibrillation counts and anti-tachycardia pacing data. Complications such as hematomas, vascular injuries, and nerve damage will be recorded. Data are collected using a secure electronic system, with effectiveness measured by arrhythmic event reduction in the 12 hours following PSGB compared to the 12 hours prior. The study plans to enroll patients over several years with ongoing safety and outcome evaluations.
Actively Recruiting
Researchers are investigating whether using a genetic test called Prosigna4 can help decide if chemotherapy is necessary for premenopausal women with hormone receptor-positive HR and HER2-negative breast cancer. This study aims to determine if treatment guided by this test produces similar outcomes to the standard approach of systematic chemotherapy. The trial focuses on younger women who often experience more side effects from chemotherapy, affecting their quality of life and work capacity. Participants will be randomly assigned to one of two groups. In the experimental group, treatment depends on the Prosigna4 score women with a high score above 60 will receive chemotherapy plus hormone therapy, while those with a lower score will receive only hormone therapy with ovarian suppression. The control group will receive the standard treatment of chemotherapy followed by hormone therapy. The study includes a pre-inclusion period for eligibility testing and randomization. Throughout the study, participants will complete questionnaires about quality of life, treatment side effects, emotional well-being, and other health measures for up to five years after randomization. Researchers will monitor cancer recurrence, survival, fertility, osteoporosis, cardiovascular disease, and other outcomes. Regular assessments include physical activity levels, adherence to therapy, and patient perceptions of treatment and participation, aiming to evaluate the safety and impact of treatment guided by the genetic test.